Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).doi:10.1200/JCO.2024.42.16_suppl.506133115061#Background:Mevrometostat (M; PF-06821497) is a potent and selective small ...
Phase I trial of MDXH210 (FeγRI×HER-2/neu, bispecific antibody) in combination with G-CSF in patients with metastatic breast cancer: H. van Ojik1, G. Groenewegen1, R. Repp3, T. Valerius3, A. van Oers2, N.A.C. Westerdaal2, Y. Deo4, G.H. Blijham1, J.G.J. van de ...
ObjectiveThe aim was to determine the response rate and toxicity of topotecan administered Days 1–3 every 21 days for recurrent epithelial cancers of the ... JV Brown,WA Peters,MA Rettenmaier,... - 《Gynecologic Oncology》 被引量: 66发表: 2003年 Phase II evaluation of nanoparticle albumin-...
摘要: Original Article from The New England Journal of Medicine — 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related Complex — A Phase I Trial关键词: acquired immune deficiency syndrome adverse effects AIDS related complex analogues Antiviral agents...
“Raludotatug deruxtecan has shown promising activity in a Phase 1 trial of patients with advanced ovarian cancer,” said Mark Rutstein, MD, global head, oncology clinical development, Daiichi Sankyo. “The REJOICE-Ovarian01 trial, which is our first trial ...
(NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer’s disease (AD) NEW HAVEN, ...
Sepofarsen was observed to be generally well-tolerated. Consistent with the findings observed in the Phase 1/2 trial, cataracts, CME, and retinal thinning were observed. “This was not the outcome we had hoped for and we share in the disappointment many are feeling in ...
A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC) K Oesterlind,JM Sanchez,P Zatloukal,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2004年 Efficacy and safety of single-agent pertuzumab, a human epidermal receptor ...
The “Phase 2 randomized, double-blind, placebo-controlled crossover trial to evaluate the safety, tolerability, and efficacy of subcutaneous injections of elamipretide (MTP-131) in subjects with genetically confirmed Barth syndrome followed by an open-label treatment extension (SPIBA 201)” (Clinic...
This phase II trial was initiated to evaluate the pCR rate of docetaxel as a single agent followed by FEC 100 in the neoadjuvant setting. Eligible patients (pts) with histologically proven breast cancer, measurable lesions >2 cm were scheduled to receive 4 cycles of chemotherapy with a day 1...